LumiraDx Products & Reviews

Next-generation point of care diagnostic platform - Next-generation microfluidic technology on the LumiraDx Platform enables lab-comparable performance across a broad menu of diagnostic assays.

The LumiraDx CRP Test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify CRP levels in whole blood and plasma. Used with the LumiraDx Platform, the Test delivers rapid, quantitative results in 4 minutes at the point of care.

The LumiraDx D-Dimer Test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify D-Dimer levels in whole blood and plasma. It is the only direct fingerstick D-Dimer assay available today*, aiding healthcare professionals to exclude deep vein thrombosis (DVT) and pulmonary embolism (PE) in symptomatic patients with confidence** - in only 6 minutes.

The LumiraDx HbA1c test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify HbA1c in fingerstick and venous whole blood. Used with the LumiraDx Platform, the LumiraDx HbA1c test delivers rapid, reliable results in approximately < 7 minutes at the point of care.

The LumiraDx INR Test measures prothrombin time reported as International Normalized Ratio (INR) from a single, direct fingerstick blood sample – all in less than 90 seconds*. The Test is used for monitoring patients on oral anticoagulation therapy with Vitamin-K Antagonist (VKA) drugs. Used with the LumiraDx Instrument, the Test delivers rapid results at the point of care.

The LumiraDx NT-proBNP test is an easy to use, fast microfluidic immunoassay designed to rapidly quantify NT-proBNP in human capillary and venous whole blood and plasma samples (Lithium Heparin). Used with the LumiraDx Platform, the LumiraDx NT-proBNP test delivers rapid, reliable results in 12 minutes at the point of care.

The LumiraDx SARS-CoV-2 Ab Test is a microfluidic immunofluorescence assay for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform the Test delivers rapid results at the point of care.

The LumiraDx SARS-CoV-2 Ag Test is a microfluidic immunofluorescence assay for the direct and qualitative detection of nucleocapsid protein antigen in nasal and nasopharyngeal swab specimens from individuals suspected of COVID-19 or asymptomatic individuals. Used with the LumiraDx Platform the test delivers rapid results at the point of care.

Lab-comparable results in just 5 minutes - With excellent performance and results in just 5 minutes, the LumiraDx SARS-CoV-2 Ag Ultra test enables you to accurately and confidently test more patients, optimize clinic workflows and help triage patients without delay

The LumiraDx SARS-CoV-2 Ag Pool Test is a rapid microfluidic immunofluorescence assay for the qualitative detection of the nucleocapsid protein antigen in nasal or nasopharyngeal swab specimens pooled from up to 5 individuals suspected of COVID-19 or up to 5 asymptomatic individuals. Used with the LumiraDx Platform the test offers a rapid, scalable and cost-effective screening solution for infectious individuals.

Is it COVID-19? Is it Flu? Lab-comparable results in minutes. Verify potential infection quickly with a rapid microfluidic assay that provides actionable and lab-comparable results in 12 mins for patients suspected of Flu and/or COVID-19, to help decision making and guide treatment.

Is it RSV? Is it COVID-19? Actionable results in minutes. Verify potential infection and help guide infection control measures quickly with a rapid microfluidic assay that provides actionable results in 12 minutes, for patients suspected of RSV and/or COVID-19.